(Q36652555)

15 August 2017

1 reference

title

Monitoring of minimal residual disease in leukemia, advantages and pitfalls (English)

1 reference

15 August 2017

Giovanni Cazzaniga

1

1 reference

15 August 2017

Giuseppe Gaipa

series ordinal

2

1 reference

15 August 2017

Vincenzo Rossi

series ordinal

3

1 reference

15 August 2017

Andrea Biondi

series ordinal

4

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

15 August 2017

1 reference

15 August 2017

38

1 reference

15 August 2017

512-521

1 reference

15 August 2017

7

1 reference

Minimal residual disease in leukaemia patients

15 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Determination of minimal residual disease in leukaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Molecular genetics of acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Genetics of myeloid malignancies: pathogenetic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Results of minimal residual disease (MRD) evaluation and MRD-based treatment stratification in childhood ALL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Risk-adapted treatment according to minimal residual disease in adult ALL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600978123

10.1080/07853890600978123

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference